Category: ‘Clinical Trials and Studies’
Posted on May 31st, 2019
Kent Stephenson is on a treadmill, working to put one foot in front of the other as a team of trainers helps guide his legs. There’s a harness holding him upright, but Stephenson is, in a sense, walking again — 10 years after a motocross accident left him paralyzed.
Posted on May 29th, 2019
InVivo Therapeutics Announces Enrollment of First Two Patients into the INSPIRE 2.0 Study for the Treatment of Acute Spinal Cord Injury
InVivo Therapeutics Holdings Corp. today announced that the first two patients have been enrolled into The INSPIRE 2.0 Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury).
Posted on January 25th, 2014
A Winnipeg paramedic has become the first Canadian to take part in an international clinical trial involving the treatment of spinal cord injuries using stem cells.
Alex Petric was injured last year during a winter vacation in Panama.
“I misjudged the water and just dove in,” the 29-year-old recalls. “I hit shallow water and became paralyzed immediately.”
Petric, now a paraplegic, became involved with the trial just four months after his injury.
Posted on August 4th, 2012
The FDA’s go-ahead makes The Miami Project’s clinical trial to aid against spinal cord injury the only one in the United States.
The Miami Project to Cure Paralysis said Tuesday it has received federal approval to conduct “revolutionary” human trials to transplant a patient’s own Schwann cells, found mainly in the nervous system, to the site of recent spinal cord injuries in the hope that the trials may bring researchers closer to finding a cure for paralysis.
Posted on September 24th, 2010
Northwestern Medicine is the first site open for enrollment in a national clinical research trial of a human embryonic stem cell-based therapy for participants with a subacute thoracic spinal cord injury. Following the procedure, participants will receive rehabilitation treatment at The Rehabilitation Institute of Chicago (RIC).
Northwestern also is the lead site of the trial, sponsored by Geron Corporation. The trial eventually will include up to six other sites and enroll up to 10 participants nationally.